Stocks · Health care · Biological Products, (No Diagnostic Substances)

Kymera Therapeutics, Inc.

KYMR Clue Score27
United States Fiscal year ends December CIK 0001815442 Results filed 29 Oct 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Bruce N. Jacobs
2 Jun 2026
Chief Financial Officer
Exercised, kept
12,653
$2.08
$26.32K
Pamela Esposito
19 May 2026
Director
Exercised, kept
1,000
$31.20
$31.20K
Bruce N. Jacobs
18 May 2026
Chief Financial Officer
Exercised, kept
15,000
$2.08
$31.20K
Nello Mainolfi
5 Jan 2026
Chief Executive Officer
Exercised, kept
3,118
$32.07
$99.99K
Nello Mainolfi
17 Dec 2025
Chief Executive Officer
Exercised, kept
2,595
$38.53
$99.99K
Showing 250 of 595 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 265
Amendments (4/A) skipped 3
Filings about a different issuer 0
Unreadable filings 0
Joint filings 34
Sales on a Rule 10b5-1 plan 184
Sales straight out of an exercise 200
Sales at will 132
Transactions with no price 0
Shares from compensation/vesting 29,275,899
Sales filed before the plan box existed 72
History held since 21 Aug 2020